; The overall goal of the Functional Genomics/Genomic Sequencing Core (FGC) is to provide state-of-the-art instruments, and expert scientific and technical advice in cancer genomics to COHCCC investigators. The FGC is equipped with major genomics instrumentation such as Affymetrix GeneChip? Analysis System, Agilent scanner/microarray system, Roche NimbleGen MS200 microarray scanner/system, lllumina HiScanSQ, HiSeq2000, GA llx and Roche 454 FLX. The core also has a next-generation ABI Taqman Realtime PCR system ViiA 7 for microarray validation. FGC provides comprehensive genomic support including transcriptomic and mlRNA/smRNA profiling by,microarrays and RNA-Seq/smRNA-Seq, ChlP-Chip/ChlPSeq, DNA methylation, DNA-Seq including whole genome and target genome sequencing, microarray genome-wide and custom genotyping, SNP/CNV, aCGH, RNAi and qRT-PCR. The FGC has recently set up numerous new genomic technologies and assays including microarray-coupled genome-wide gene expression profiling using difficult clinical formalin-fixed paraffin-embedded (FFPE) RNA samples, smRNASeq and RNA-Seq using FFPE-derived samples, microfluidic chip- and microarray-coupled single-cell genome-wide gene expression profiling. In addition, the FGC has implemented NimbleGen array-based comprehensive high-throughput arrays for relative methylation (CHARM), Affymetrix DMET and genomewide human SNP 6.0 array genotyping, and lllumina Infinium HumanMethylation450 BeadChip that interrogates more than 450,000 methylation sites across the whole human genome at single-nucleotide resolution. The FGC has supported numerous NIH/NCI projects resulting in high impact publications. In summary, the advanced genomic tools in the FGC allow COHCCC investigators to: 1) identify cancer gene mutations at high-throughput rates;2) map cancer genomic, transcriptomic and epigenomic fingerprints to identify genomic biomarkers for cancer early detection and diagnosis;3) identify novel therapeutic targets against cancers;and 4) predict responses to therapy.
The overall goal of the Functional Genomics Core facility is to provide state-of-the-art instruments, scientific and technical advice in cancer genomics. These allow us to potentially identify markers for cancer early detection and the novel targets for cancer therapy. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
| Chaurasiya, Shyambabu; Chen, Nanhai G; Fong, Yuman (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83-90 |
| Liu, Stephen V; Groshen, Susan G; Kelly, Karen et al. (2018) A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 82:723-732 |
| Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55 |
| Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60 |
| Murray, Jennifer; Whitson, Robert H; Itakura, Keiichi (2018) Reduced prostaglandin I2 signaling in Arid5b-/- primary skeletal muscle cells attenuates myogenesis. FASEB J 32:1868-1879 |
| Dufva, Olli; Kankainen, Matti; Kelkka, Tiina et al. (2018) Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567 |
| Chen, Steven F; Liu, Zheng; Chaurasiya, Shyambabu et al. (2018) Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget 9:20451-20466 |
| Petrossian, Karineh; Nguyen, Duc; Lo, Chiao et al. (2018) Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. Breast Cancer Res Treat 170:499-506 |
| Abeywardana, Tharindumala; Oh, Myungeun; Jiang, Lei et al. (2018) CARM1 suppresses de novo serine synthesis by promoting PKM2 activity. J Biol Chem 293:15290-15303 |
| Sun, Virginia; Crane, Tracy E; Slack, Samantha D et al. (2018) Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. Contemp Clin Trials 68:61-66 |
Showing the most recent 10 out of 1396 publications
